Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Shares (2023)

PharmaCyte Biotech (PMCB) has disclosed Preferred Shares for 4 consecutive years, with $20.0 million as the latest value for Q3 2023.

  • On a quarterly basis, Preferred Shares changed N/A to $20.0 million in Q3 2023 year-over-year; TTM through Jul 2023 was $20.0 million, a N/A change, with the full-year FY2013 number at $580000.0, changed 0.0% from a year prior.
  • Preferred Shares was $20.0 million for Q3 2023 at PharmaCyte Biotech, up from $500000.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $20.0 million in Q3 2023 to a low of $20.0 million in Q3 2023.